RhinoMed sleep trial results positive

About the author:

Author name:

By Scott Power

Job title:

Senior Analyst

Date posted:

03 December 2014, 11:59 AM

Sectors Covered:

Healthcare, Life Sciences

What happened

RhinoMed (RNO) achieved its primary endpoint in an independently conducted sleep trial (n = 236, 118 subjects + 118 partners) to test impacts on the soon to be launched "Mute" product has on the user and user's partner.

Results validate product as an over-the-counter (OTC) solution to snoring and night-time nasal congestion market.

Primary endpoint was to evaluate the impact of the Mute technology on both snoring and sleep quality.

Evidence of benefit in the Snorer group was clear with 75% of respondents reporting a reduction in their snoring and 78% reporting an improvement in their ability to breathe at night.

The Partner group reported a significant reduction in the snoring severity (73%), volume (67%), frequency (63%) and duration (65%).

Impact to forecasts and view

Low liquidity stock but a positive result and should see a small bounce today. No impact to forecasts at this stage. Mute should end up contributing a large portion of RNO's future revenue stream - look forward to 2Q sales figures end of January.

More information

Morgans clients can login to view the latest research on RhinoMed. Alternatively contact your adviser or nearest Morgans office for more information.

Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited ABN 49 010 669 726 as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited, its related bodies corporate, directors and officers, employees, authorised representatives and agents ("Morgans") do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.